UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison between behavioral and structural explanation in learning by model-building

Research and practice in technology enhanced learning, 2019-03, Vol.14 (1), p.1-17, Article 6

2019

Volltextzugriff (PDF)

Evaluation of the Function that Detects the Difference of Learner’s Model from the Correct Model in a Model-Building Learning Environment

Human Interface and the Management of Information: Supporting Learning, Decision-Making and Collaboration, p.40-49

Volltextzugriff (PDF)

Behavioral Explanation versus Structural Explanation in Learning by Model-Building

Artificial Intelligence in Education, p.139-144

Volltextzugriff (PDF)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Cancer science, 2022-09, Vol.113 (9), p.3169-3179

2022

Volltextzugriff (PDF)

Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression

International journal of molecular sciences, 2020-10, Vol.21 (19), p.7121

2020

Volltextzugriff (PDF)

Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance

Journal of gastroenterology, 2020-12, Vol.55 (12), p.1183-1193

2020

Volltextzugriff (PDF)

MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression

Genes, 2022-12, Vol.14 (1), p.100

2022

Volltextzugriff (PDF)

Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2216

2023

Volltextzugriff (PDF)

Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression

International journal of hematology, 2023-04, Vol.117 (4), p.563-577

2023

Volltextzugriff (PDF)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

BMC cancer, 2021-07, Vol.21 (1), p.1-12, Article 795

2021

Volltextzugriff (PDF)

Sub-lethal doses of chemotherapeutic agents induce senescence in T cells and upregulation of PD-1 expression

Clinical and experimental medicine, 2023-10, Vol.23 (6), p.2695-2703

2023

Volltextzugriff (PDF)

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)

Breast cancer research and treatment, 2023-10, Vol.201 (3), p.409-415

2023

Volltextzugriff (PDF)

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

Investigational new drugs, 2021-02, Vol.39 (1), p.217-225

2021

Volltextzugriff (PDF)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

Breast cancer (Tokyo, Japan), 2018-07, Vol.25 (4), p.438-446

2018

Volltextzugriff (PDF)

Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma

British journal of haematology, 2017-11, Vol.179 (3), p.449-460

2017

Volltextzugriff (PDF)

Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-08, Vol.26 (8), p.865-869

2020

Volltextzugriff (PDF)

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1015-1015

2023

Volltextzugriff (PDF)

Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13031-e13031

2023

Volltextzugriff (PDF)

SF3A1 Gene Polymorphism Affects Clinical Features, but not Susceptibility to Myelodysplastic Syndromes

The Kitakanto Medical Journal, 2020/11/01, Vol.70(4), pp.315-323

2020

Volltextzugriff (PDF)

IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma

Clinical and experimental medicine, 2021-05, Vol.21 (2), p.323-329

2021

Volltextzugriff (PDF)

Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018

Clinical and experimental nephrology, 2019-01, Vol.23 (1), p.1-15

2019

Volltextzugriff (PDF)

Real-world effectiveness of post-T-DM1 treatments in HER2-positive metastatic breast cancer: KBCSG-TR1917 observational study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e13020-e13020

2020

Volltextzugriff (PDF)

P-Chirogenic Diaminophosphine Oxide: A New Class of Chiral Phosphorus Ligands for Asymmetric Catalysis

Journal of the American Chemical Society, 2004-03, Vol.126 (12), p.3690-3691

2004

Volltextzugriff (PDF)

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016)

Journal of intensive care, 2018-02, Vol.6 (1), p.7-7, Article 7

2018

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Aktive Filter

ThemaMagnetic Resonance Imaging

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(58)
Tagungsberichte
(2)

Sprache

Englisch
(58)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison between behavioral and structural explanation in learning by model-building

Evaluation of the Function that Detects the Difference of Learner’s Model from the Correct Model in a Model-Building Learning Environment

Behavioral Explanation versus Structural Explanation in Learning by Model-Building

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression

Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance

MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression

Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression

Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

Sub-lethal doses of chemotherapeutic agents induce senescence in T cells and upregulation of PD-1 expression

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma

Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03

SF3A1 Gene Polymorphism Affects Clinical Features, but not Susceptibility to Myelodysplastic Syndromes

IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma

Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study

Real-world effectiveness of post-T-DM1 treatments in HER2-positive metastatic breast cancer: KBCSG-TR1917 observational study

P-Chirogenic Diaminophosphine Oxide: A New Class of Chiral Phosphorus Ligands for Asymmetric Catalysis

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016)

Aktive Filter

Suchergebnisse filtern